This study will evaluate if allogeneic human induced pluripotent stem cell (iPSC)-derived motor neuron progenitor cells (XS228, made by XellSmart) can safely and effectively treat subacute spinal cord injury. Researchers at the Third Affiliated Hospital, Sun Yat-Sen University, in collaboration…
Brainstorm Therapeutics is back, and they've learned a lot from their previous trials. If you don't know the history of Nurown, their ALS stem cell candidate, it showed early promise in Phase 2 with some slowed disease progression. In Phase…
Biotech company YiPSCELL breaks ground on a new trial, will head to safety & efficacy trials soon.
Will adipose stem cell therapy hold an answer for neuroinflammation, a factor in Alzheimer's?
This follows their RMAT designation, and promising Phase 1/2 trial results, which they presented earlier this year.
BioCardia plans to move forward with enrollment of up to 39 participants in the United States.
The trial leverages Calidi’s innovative virotherapy platform, offering new hope for combating this aggressive form of brain cancer.
Hope Biosciences has reportedly received FDA authorization to conduct a pediatric clinical trial using their adipose(fat)-derived mesenchymal stem cells (HB-adMSCs) to assess their impact on juvenile idiopathic arthritis (JIA) in children aged 2 to 16. This trial aims to determine…
Phase III exPDite-2 trial follows completion and discussion of Phase I trial data with US FDA under Regenerative Medicine Advanced Therapy (RMAT) designation exPDite-2 is a randomized, sham surgery-controlled double-blind trial assessing efficacy and safety of bemdaneprocel in people living…